Kornimate/medical-research-clean huggingface dataset:
multimodal retinal imaging of cerebrovascular stroke

Conditions: Stroke; Cerebrovascular Accidents

Summary: the hypothesis is that in patients with stroke, abnormalities of retinal microvascularization shown on color fundus photography and the depletion of retinal capillary density evaluated by oct-a are markers of acute impairment of microcirculation of the central nervous system and are correlated with lesions on brain imaging. patients hospitalized for stroke mri-confirmed, will be included. an ophthalmologic assessment including color fundus photography (cfp) and oct-a will be carried out after stabilization and at 3 months follow-up. outcomes assessor will be blinded.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke * with cerebral microangiopathy (defined by a svd score \> 1) exclusion criteria: * acute hemorrhagic stroke * anophthalmia

Keywords: optical coherence tomography (oct-a) color fundus photography (cfp) retinal microvascularization cerebral microangiopathy
treatment of peyronie's disease with platelet-rich plasma

Conditions: Peyronies Disease

Summary: the purpose of this pilot study is to optimize a planned randomized, double-blind, placebo-controlled clinical trial evaluating the effects of platelet-rich plasma (prp) intralesional injections in men affected by peyronie's disease (pd) in the fibrotic phase. the pilot study aims to identify potential challenges in the practical execution of the clinical trial, particularly regarding prp preparation and the blinding process. furthermore, it seeks to evaluate the effects of prp injections.

the study protocol is structured such that participants, after being informed about the project and providing consent, will attend a baseline visit where relevant data will be collected from the participant, questionnaires, the patient's medical record, and through an objective examination. subsequently, participants will attend weekly injection sessions for 6 weeks, during which they will receive 3 prp injections and 3 saline injections (placebo) in a randomized order. three months after the final injection, participants will attend a follow-up visit, where the final data will be collected. analysis will then be conducted.

Eligibility criteria:
inclusion criteria: * 18 years or older * be able to provide written informed consent * diagnosis of pd without active pain and without progressive curvature over the past 3 months (fibrotic phase). * penile curvature of 30-95 degrees exclusion criteria: * erectile dysfunction unresponsive to on-demand pde5 inhibitors * hourglass malformation * severely calcified plaques where injection is considered unfeasible * history of priapism. * history of penile fracture. * previous treatment for pd with injections and/or surgery.

Keywords: prp platelet-rich plasma
post-marketing safety study in patients with moderate renal insufficiency who receive omniscan for contrast-enhanced magnetic resonance imaging (mri)

Conditions: Chronic Kidney Disease; Renal Insufficiency

Summary: this will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, omniscan, during a mri. omniscan will be administered intravenously at the medical discretion of the prescribing physician.


Eligibility criteria:
inclusion criteria: * the subject has been referred for a clinically indicated mri examination with a gadolinium-based contrast agent. * the subject has known or suspected chronic kidney disease with an egfr greater than or equal to 30ml and \<60 ml/min/1.73 m2 as measured within 30 days prior to the planned index omniscan administration. * the subject agrees to be contacted for follow-up for 24 months. exclusion criteria: * patients with known or suspected nsf based on biopsy confirmation or the onset of signs and symptoms of nsf lasting at least 7 days as follows: 1. skin - swelling, hardening and tightening; reddened or darkened patches; burning or itching; 2. eyes - yellow raised spots on whites of eyes; or 3. bones and muscle - stiffness in joints; difficulty in moving or straightening of arms, hands, legs or feet; bone pain especially in hips and ribs or muscle weakness. * patients allergic to any gbca. * patients with chronic renal disease with a gfr \<30 ml/min/1.73 m2 as measured within 30 days prior to the planned omniscan administration. * patients with acute renal insufficiency of any severity due to the hepato-renal syndrome or in the peri operative liver transplantation period.

Keywords: ckd - chronic kidney disease gbca - gadolinium-based contrast agent gfr - glomerular filtration rate mri - magnetic resonance imaging nsf - nephrogenic systemic fibrosis known or suspected ckd with an egfr greater than or equal to 30ml & less than 60 ml/min/1.73m2 as measured within 30 days prior to the omniscan.
impact of the nurse visit on observance of the intake of oral carcinological treatment in the elderly

Conditions: Oncology, Gerontology

Summary: the increasingly used oral anticancer treatments allow the patient to reduce treatment and social constraints to reduce hospitalization costs. the counterpart is a decrease in the monitoring of the correct intake of drugs and the detection of side effects. these two risks are major in the elderly, due to comorbidities, poly-medication and decreased attention. the project objective to evaluate the impact of a bi-weekly nursing visit to the patients' homes for 3 months, compared to a conventional management without a nursing visit. it is a prospective, randomized, controlled, multicenter study to include 224 patients over 18 months. the impact will be assessed by counting the tablets not taken and by filling an observation booklet with the nurse at home.


Eligibility criteria:
inclusion criteria: * patient aged 70 and over * patient initiating an oral anticancer treatment (chemotherapy, targeted therapy, 2nd generation hormone therapy type acetate abiraterone and enzalutamide) * patient who received an onco-geriatric assessment * patient with informed consent signed exclusion criteria: * patient in a medical institution * patient under exclusive hormone therapy * patient already eligible for nurse support * patient not speaking french * patient under tutelage and guardianship or under safeguard of justice * patient already included in a research protocol * patient sharing his or her home with a person receiving nursing care at home more than once a week and for a period longer than 1 month after the patient's inclusion.
the novel approach of minimally invasive parathyroid surgery requires precise identification and localization of the lesion prior to exploration

Conditions: Hypercalcemia; Hyperparathyroidism

Summary: purpose of this study is to compare the image quality and diagnostic accuracy obtained with ultrafast solid state short spect in comparison with the routine spect protocol.

single-tracer, dual-phase tc-mibi parathyroid scintigraphy is based on the differential washout rate of the tracer (mibi) from the thyroid and the parathyroid tissue. a distinct focus of increased mibi uptake relative to the thyroid gland, either on the early or late image or on both, or a focal uptake in the mediastinum, is considered positive for abnormal parathyroid tissue. tc99m-mibi planar scintigraphy was found to play a major role in the preoperative localization of a parathyroid adenoma (pta), with a sensitivity ranging from 85% to 95% and specificity of up to 99%. subsequently, the use of mibi- single photon emission computed tomography (spect) significantly improved the sensitivity of the test and improved the accuracy of lesion localization. a limitation of adding the spect component is related to its relatively long duration. the duration of a mibi-spect acquisition of neck and the mediastinal area may take up to 15-20 minutes using a standard nuclear medicine camera. long acquisition time may lead to patient discomfort and movement resulting in image degradation, artifacts and may lead to overall decreased diagnostic accuracy. a reduced spect acquisition time without image quality degradation may decrease patient discomfort and increase clinical throughput. an ultrafast solid state czt camera (ge healthcare discovery 570c) is currently used for routine cardiac spect imaging achieving high quality cardiac studies for a significantly shorter acquisition time. present study evaluates the potential use of the ultrafast camera in patients with a clinically suspected pta who perform tc-mibi imaging.

Eligibility criteria:
inclusion criteria: 1) the subject is 18 years old or older. (2) the subject is clinically suspected or known to have parathyroid adenoma and is scheduled to have a mibi study as part of his/her standard clinical evaluation. (3) the subject is able and willing to comply with the additional procedure (ultrafast mibi spect) and a signed and dated informed consent is obtained before any procedure for study purposes is performed. exclusion criteria: 1. pregnancy. 2. psychosis or any other condition, which, in the investigators opinion would prevent adherence to the study protocol.
cystic fibrosis transmembrane regulator (cftr) biomarker study to evaluate the rescue of mutant cftr in patients with cystic fibrosis treated with cftr-modulators

Conditions: Cystic Fibrosis

Summary: this observational study evaluates the effect of therapy with cystic fibrosis transmembrane regulator (cftr) modulators on cftr function measured by the cftr biomarker intestinal current measurement (icm), nasal potential difference (npd) and sweat chloride in a post-approval setting in patients with cystic fibrosis (cf).

cystic fibrosis transmembrane regulator (cftr) biomarker (intestinal current measurement (icm), nasal potential difference (npd), sweat chloride) before the start of therapy and 12 and 52 weeks after initiation of therapy clinical parameters (anthropometry, lung function, lung magnetic resonance imaging (mri), lung computer tomography (ct)) before the start of therapy and after initiation of therapy assessment of airway secretion specimens before the start of therapy and after initiation of therapy

Eligibility criteria:
inclusion criteria: * decision for cystic fibrosis (cf) transmembrane regulator (cftr)-modulator therapy by the patient and the caring cf physician * signed informed consent form (icf) and, where appropriate, signed assent form. exclusion criteria: * ongoing participation in an investigational drug study (including studies investigating lumacaftor, tezacaftor or ivacaftor)

Keywords: cftr icm npd
lidocaine infusion treatment for subarachnoid hemorrhage headaches

Conditions: Subarachnoid; Hemorrhage, Nontraumatic; Headache

Summary: the goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. through this prospective analysis, we hope to: 1. show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderate/severe headache pain following non-traumatic subarachnoid hemorrhage; 2. show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage; 3. and report vasospasm prevalence in the cohort. participants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores (on a numeric pain scale) every two hours they are awake for a maximum of seven days. monitoring for vasospasm will occur as part of their regular medical care.


Eligibility criteria:
inclusion criteria: for study recruitment, patients must be 18 years or older, have a favorable neurological status defined as hunt and hess score ≤ 3 (as it accounts for patient awareness), can communicate numeric pain scores, and are diagnosed with non-traumatic subarachnoid hemorrhage. exclusion criteria: patients will be excluded from study consideration if they are diagnosed with traumatic subarachnoid hemorrhage, if they are \ 3 days of hospitalization, if they had a prior aneurysm, chronic pain not associated with non-traumatic subarachnoid hemorrhage diagnosis, a disability before the stroke (\> 2 on modified rankin scale score), a hunt and hess score \> 3, or contraindications to lidocaine (significant cardiac disease, arrhythmia, seizures, previous allergic reaction to lidocaine.

Keywords: nontraumatic subarachnoid hemorrhage headache lidocaine infusion
ledderhose disease: radiotherapy or not?

Conditions: Ledderhose Disease

Summary: the aim of the ledrad trial is to determine the efficacy and durability of radiotherapy as treatment for patients with ledderhose disease and to compare this to the natural course of ledderhose disease.


Eligibility criteria:
inclusion criteria: * patients with painful ledderhose disease. the pain score measured with the vas score and is at least 2 on the 11-point scale (0 = no pain to 10 = worst imaginable pain). * age ≥ 18 years * who performance status 0, 1 or 2 (appendix, section 18) * before patient randomisation, written informed consent must be given according to ich/gcp, and wmo requirements. * controlling the dutch language (speaking and reading). * able and willing to complete quality of life questionnaires in dutch * must be accessible for treatment follow-up exclusion criteria: * surgical intervention before for ledderhose disease * previous radiation treatment for ledderhose disease * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * not able to lay prone for at least fifteen minutes * females who are pregnant at entry or who want to become pregnant within six months.

Keywords: radiotherapy pain
effect of caloric restriction and protein intake on metabolism and anabolic sensitivity

Conditions: Weight Loss; Starvation

Summary: the purpose of this study is to determine if an increased protein intake can attenuate the suppression of metabolic and anabolic hormones during caloric restriction

1. preliminary testing prior to the study start, participants will be weighed and body composition will be determined using calipermetry (7 sites) and bioelectrical impedance. peak oxygen uptake (vo2peak) will be assessed using an incremental exercise test on a bicycle ergometer. 2. randomization participants will proceed through each of the following conditions lasting 5 days: cr-lp: participants will be restricted to 30 kcal/kg ffm/day and protein intake will be low (0.8 g/kg bw/day). cr-hp: participants will be restricted to 30 kcal/kg ffm/day and protein intake will be high (1.7 g/kg bw/day). con: participants will be in energy balance and consume 1.7 g protein/kg bw/day. 3. diet prescription dietary energy intake will be controlled using clinical products and maltodextrin to meet target energy intakes. participants will received calcium and vitamin d supplementation throughout the study. 4. exercise prescription during all conditions, participants will conduct daily supervised exercise on a bicycle ergometer at an exercise intensity of 60% vo2peak. exercise duration will be adjusted individually such that exercise energy expenditure will amount to 15 kcal/kg ffm/day. additional exercise and intense physical activity will be prohibited. 5. assessments the following assessments will be conducted prior to the start of each condition as well as upon completion of each condition: body weight and composition (impedance), fasting blood draw for assessment of metabolic and anabolic hormones, resting metabolic rate, aerobic fitness (vo2peak), and questionnaires. 6. washout once a participant has completed a study condition, participant will be allowed a washout of at least 14 days to allow protein balance to return to baseline (hoffer \& forse, 1990). during this time, participants will resume their regular diet and physical activity.

Eligibility criteria:
inclusion criteria: * 4 hours/week of purposeful aerobic exercise over the last 3 months * body mass index: 19-25 kg/m2 * \< 15% body fat exclusion criteria: * cardiovascular disease risk factors that would result in greater than low risk * smoking * type i, type ii diabetes, or history of high fasting glucose; * history of high blood pressure and/or use of medication for hypertension; * history of dyslipidemia, or on lipid-lowering medication; * underlying health condition and/or use of medication that could interfere with any of our study outcomes. * history or current diagnosis of a clinical eating disorder * failure to adhere to study protocol
use of preanesthetic dexmedetomidine in elderly, treated-hypertensive patients

Conditions: Perioperative Care

Summary: background: dexmedetomidine is an alpha 2 adrenergic agonist with sedative, anxiolytic, and analgesic properties. this study was designed to evaluate the inhibitory effects of preoperative 0.5 μg/kg dexmedetomidine on hemodynamic responses caused by endotracheal intubation in elderly patients being treated for hypertension. methods: forty elderly (≥ 65 years) treated-hypertensive patients of american society of anesthesiologists physical status ii undergoing elective noncardiac surgery were randomly and assigned to two groups. group c received normal saline and group d received 0.5 μg/kg dexmedetomidine intravenously over 10 min just before endotracheal intubation. systolic blood pressure (sbp), diastolic blood pressure (dbp), mean arterial pressure (map) and heart rate (hr) were recorded preoperatively at ward, immediately after study drug administration, and at 1, 3, and 5 minutes after endotracheal intubation.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status ii * scheduled for elective noncardiac surgery * being treated with anti-hypertensive medication exclusion criteria: * endotracheal intubation attempted more than twice * morbidly obese (bmi \> 35 kg/m2)

Keywords: dexmedetomidine
tens trial to prevent neuropathic pain in sci

Conditions: Spinal Cord Injuries

Summary: the purpose of this research study is to: 1) test whether transcutaneous electrical nerve stimulation (tens) after spinal cord injury can reduce the onset of post-injury neuropathic pain; and 2) to learn more about this kind of pain and who is at risk for suffering from this type of pain after spinal cord injury. neuropathic pain is a type of pain that occurs in about 50% of people with spinal cord injury. this type of pain is usually described as "burning" or "tingling," and is present around the level of injury and/or in areas below the level of injury. the investigators' goal is to try a non-drug treatment (tens) that may help prevent this pain from occurring. pain symptoms will be compared between the study participants who receive active tens and the study participants who receive a sham tens treatment.


Eligibility criteria:
inclusion criteria: * age ≥ 18; * traumatic spinal cord injury; * date of injury occurring within four months of study enrollment. exclusion criteria: * more than four months since date of injury; * contraindications for the study intervention, transcutaneous electrical nerve stimulation (tens),88 including: * implanted electronic device such as a pacemaker; * cardiovascular problems; * pregnancy; * epilepsy; * cancer; * persons with a spinal cord injury at the c2 level, as placement of tens electrodes on the neck is not recommended; * cognitive dysfunction which limits the ability of the participant to adequately understand procedures and risks. * prisoners * pregnant women special populations: * adults unable to consent: excluded from study * individuals -who are not yet adults: individuals who are less than 18 years old will be excluded from the study * pregnant women: women who are known to be pregnant will not be recruited into the study. a pregnancy test will be administered to females prior to enrollment in tens (or sham) treatment. women who become pregnant before or during the 8-week tens treatment period will be discontinued from the study. women who become pregnant after the 8-week tens treatment portion of the study will continue to be enrolled, and followed according to protocol guidelines (no information will be collected specifically on the pregnancy or fetus). * prisoners: excluded from study * neonates: not applicable

Keywords: neuropathic pain transcutaneous electrical nerve stimulation
release versus post isometric relaxation among futsal players with shin splints

Conditions: Shin Splint

Summary: the aim of the study is to determine the effects of myofascial release versus post isometric relaxation among futsal players with shin splints

previous literature did not compare the combined effects of both myofascial release and post isometric relaxation technique inn sgin splints patients so the purpose of this study is self-explanatory, with the basic goal of comparing these two techniques to determine their effects on patient pain, and functional disability thus improving overall performance of the futsal players.this study will be helpful in proposing proper treatment for shin splint, to make people aware of the condition rehabilitation and improving performance of the futsal players undergoing the condition. thus it will be useful for the betterment of the players overall health and wellbeing.

Eligibility criteria:
inclusion criteria: * subjects have leg pain with exertion of more than 1 or 2 hours * participants age 20-30 years * participants have mtss for more than 2 weeks * subjects have no previous history of trauma to legs * subject having local pain on lower anterior leg gradual cessation of the offending activity exclusion criteria: * • subjects have medical history of systemic disease * subjects have medical history of cardiovascular disease * participants with history of metastatic diseases * any trauma or pathology of lower limb participants having neuropathy of lower extremity

Keywords: shin splint myofascial release post isometric relaxation
location of glp-1 release

Conditions: Obesity

Summary: background: physicians do not have a unified, scientifically tested theory of causation for obesity and its comorbidities, nor do they have explanations for the mechanics of the metabolic/bariatric surgery procedures. integral to proffered hypotheses are the actions of the hormones glucagon-like peptide (glp-1), peptide yy (pyy), and leptin. study objective: to obtain blood levels of glp-1, pyy, and leptin after stimulation of the terminal ileum and cecum by a static infusion of a food hydrolysate in morbidly obese patients undergoing a duodenal switch procedure. methods: plasma levels of glp-1, pyy, and leptin were obtained at 0, 30, 60, 90, and 120 minutes after instillation of 240 ml of a food hydrolysate into the ileum or cecum.


Eligibility criteria:
inclusion criteria: * any patient who was qualified and approved for bariatric surgery and elected to undergo open duodenal switch procedure. exclusion criteria:

Keywords: glp-1 pyy leptin duodenal switch